Invagen Pharmaceuticals Recalls Lanthanum Carbonate Tablets for Safety Risk
Invagen Pharmaceuticals recalled Lanthanum Carbonate chewable tablets on October 24, 2025, due to stability issues. The tablets failed hardness specifications, posing a high hazard level. Healthcare providers and consumers should stop using the product immediately.
Product Details
The recall affects Lanthanum Carbonate chewable tablets, 1000mg per tablet. The product is sold in patient pack cartons containing ten 9-bottle units. The NDC codes are 76282-478-90 for the carton and 76282-478-13 for the bottle.
The Hazard
The product did not meet stability specifications, failing a hardness test. This defect could affect the product's efficacy and safety, posing a risk to patients who rely on this medication.
Reported Incidents
There are no reported injuries or incidents related to this recall. However, the potential for compromised product quality raises serious health concerns.
What to Do
Stop using the recalled Lanthanum Carbonate chewable tablets immediately. Contact Cipla USA, Inc. or your healthcare provider for further guidance.
Contact Information
For more information, contact Cipla USA, Inc. at [insert phone number] or visit their website at [insert website].